Amgen Inc. $AMGN Shares Sold by Beutel Goodman & Co Ltd.

Beutel Goodman & Co Ltd. decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 35.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 335,540 shares of the medical research company’s stock after selling 185,037 shares during the quarter. Beutel Goodman & Co Ltd. owned approximately 0.06% of Amgen worth $141,433,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. BlackRock Inc. raised its stake in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares in the last quarter. State Street Corp boosted its holdings in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Amgen by 12.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after buying an additional 605,928 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Amgen in the second quarter valued at $1,831,903,000. Finally, Amundi increased its holdings in Amgen by 15.2% during the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock worth $1,408,715,000 after buying an additional 512,883 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen’s new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

Wall Street Analysts Forecast Growth

AMGN has been the topic of several analyst reports. Guggenheim upped their price target on shares of Amgen from $378.00 to $435.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. TD Cowen lifted their price objective on shares of Amgen from $452.00 to $531.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Scotiabank lifted their price objective on shares of Amgen from $500.00 to $530.00 and gave the company a “sector outperform” rating in a research report on Wednesday, November 4th. Barclays boosted their price objective on shares of Amgen from $380.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 21st. Finally, Freedom Broker cut shares of Amgen from a “buy” rating to a “hold” rating and upped their target price for the company from $450.00 to $470.00 in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average target price of $422.76.

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Stock Up 1.0%

Shares of AMGN opened at $465.23 on Tuesday. The firm has a market cap of $251.52 billion, a P/E ratio of 20.64, a price-to-earnings-growth ratio of 3.47 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.13 and a current ratio of 1.48. Amgen Inc. has a 52 week low of $312.39 and a 52 week high of $483.99. The firm’s 50-day simple moving average is $423.08 and its 200 day simple moving average is $378.80.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. During the same period last year, the business posted $5.64 earnings per share. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, analysts forecast that Amgen Inc. will post 23.33 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is presently 58.47%.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.